Liquidia (NASDAQ:LQDA) Insider Sanjeev Khindri Sells 4,134 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 4,134 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $65.46, for a total transaction of $270,611.64. Following the completion of the sale, the insider owned 67,132 shares in the company, valued at $4,394,460.72. This represents a 5.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Up 1.9%

LQDA opened at $65.25 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78. The firm has a market capitalization of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58. The company’s 50-day moving average is $48.50 and its 200 day moving average is $40.37.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday, June 5th. Needham & Company LLC increased their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. BTIG Research increased their price objective on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research note on Thursday, June 4th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Farallon Capital Management LLC boosted its holdings in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in Liquidia in the 3rd quarter worth approximately $38,887,000. Caprock Group LLC bought a new position in Liquidia in the 3rd quarter worth approximately $37,114,000. MPM Bioimpact LLC boosted its holdings in Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC bought a new position in Liquidia in the 3rd quarter worth approximately $12,571,000. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).